Q BioMed Acquires Rights of Metastron from GE Healthcare

 Q BioMed Acquires Rights of Metastron from GE Healthcare

Q BioMed Acquires Rights of Metastron from GE Healthcare

Shots:

• GE Healthcare to receive upfront, milestone and single digit royalties for 15 yrs and Q BioMed to get rights of Metastron, in 22 approved countries
• The acquisition of Metastron will support as a non-opioid therapy to treat debilitating pain associated with skeletal cancer metastases and is expected to expand the scope of drug
• Metastron (Strontium Chloride, Sr-89) IV is a non-narcotic analgesic, indicated for reduction of bone pain palliation in metastatic cancer

Click here to read full press release/ article | Ref: Q BioMed | Image: HIT Consultant

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post